Abstract
Orally administered antipsychotic drugs are the first line of treatment in the management of psychotic disorders that affect millions of people globally and have a tremendous impact on patient and family lives, such as schizophrenia and bipolar disorder. Nevertheless, adverse drug reactions hinder clinical outcomes, resulting in patient non-compliance. The design and implementation of adequate formulation strategies for enhancing drug delivery and targeting to the brain has been a significant challenge, mainly due to the restrictive properties of the blood–brain barrier. However, recent pharmacokinetic and pharmacodynamic in vivo assays confirmed that there is evidence of the advantage of the intranasal route when compared to oral and intravenous administration, as it allows the possibility of direct nose-to-brain transport via neuronal olfactory and trigeminal pathways, reducing systemic side effects, and maximizing therapeutic outcomes. In addition, the formulation of polymeric and solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, nanoemulgels, nanosuspensions, niosomes, Spanlastics and polymeric mixed micelles is a promising approach since they have a reduced particle size, ideal for nose-to-brain delivery, stability, high encapsulation efficiency, enhanced drug solubility, and drug protection from enzymatic degradation. Nevertheless, it is essential to continue research in this field, conducting more long-term studies with greater uniformity so that the true potential of these formulations can be assessed and a transposition into the pharmaceutical industry is someday possible.
Supplementary Materials
Presentation. The material is available at https://www.mdpi.com/article/10.3390/ASEC2022-13765/s1, Presentation: The importance of nanosystems in antipsychotic drugs brain targeting.
Author Contributions
Conceptualization, P.C.P. and A.C.P.-S.; methodology, P.C.P. and A.C.P.-S.; investigation, M.F.; writing—original draft preparation, M.F.; writing—review and editing, P.C.P., A.C.P.-S. and F.V.; supervision, P.C.P., A.C.P.-S. and F.V. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).